New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

The rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to CDC provisional data. That’s down ...

GTA schools are reporting cases of a disease commonly known as “slapped cheek” syndrome — an infectious virus often appearing in school-age children. A recent letter posted on a door at a ...

and pertussis (whooping cough), Sanofi’s immunization against respiratory syncytial virus (RSV) Beyfortus, and GSK’s Rotarix and Merck’s RotaTeq, the two rotavirus vaccines licensed for use ...